Kornimate/medical-research-clean huggingface dataset:
early recovery after surgery (eras) versus conventional protocol after laparoscopic gastrectomy

Conditions: Gastric Cancer

Summary: enhanced recovery after surgery (eras) programs have been introduced with purposes of reducing the surgical stress response and obtaining optimal recovery after surgery.

there is strong evidence of the usefulness of the eras programs in patients undergoing colorectal surgery in terms of significantly reduced postoperative complications and shorter length of hospital stay, compared to the patients of conventional treatment. however, few studies exist about the implication of eras programs in the laparoscopic gastrectomy. the aim of this study was to compare the recovery rate, morbidity, and quality of life in the patients undergoing laparoscopic gastrectomy for gastric cancer, receiving either eras protocol or conventional postoperative cares.

Eligibility criteria:
inclusion criteria: * elective surgery * american society of anesthesiologists (asa) scores \< 3 * 20 \< age \< 80 * gastric cancer, adenocarcinoma, possible to perform laparoscopic distal gastrectomy * informed consent * no other treatment (radiation, chemotherapy or immunotherapy) on this gastric cancer or other type of cancer. * no systemic inflammatory disease exclusion criteria: * emergency operation

Keywords: gastric cancer eras (early recovery after surgery) fast track laparoscopic gastrectomy
disaster preparedness among families caring for children with diabetes

Conditions: Diabetes

Summary: the primary aim of the survey is to ascertain the emergency preparedness among our families with diabetes mellitus and to obtain a percentage of unprepared to the ones who are prepared. the secondary aim is to demonstrate the relationship between disaster preparedness and factors like socio-economic status, parent's marital status, ethnicity and those who had prior experience of a disaster to those who have not experienced a disaster.

this is a cross-sectional study. the subjects are the parent/parents/legal guardian, who will be coming to the clinic for their routine appointment for diabetes management. during the time in which the subject is waiting for the doctor or after their check-up, a research team member will approach the family and ask for their permission to administer the survey. the survey consists of a series of questions designed to ascertain the awareness towards emergency preparedness among families. after they have completed the questionnaire they would be given and/or mailed handouts to enhance their awareness towards disaster preparedness. potential benefits: this study will help to increase awareness regarding disaster preparedness among the surveyed families. subjects and families will gain valuable information about caring for diabetes in the event of a disaster. the potential benefit to the society is that through this study we can ascertain the primary caregiver's awareness of disaster preparedness in regard to a family member with a chronic illness. we will suggest measures to improve their competency towards dealing with disasters. we will be providing educational literature to the primary care givers in the form of handouts at the end of the survey.

Eligibility criteria:
inclusion criteria: * subjects include families of children with type 1 and type 2 diabetes mellitus attending the diabetes/ endocrine clinic at texas children hospital. exclusion criteria: * subjects excluded are families of children with illnesses other than type 1 and type 2 diabetes mellitus attending the diabetes/ endocrine clinic at texas children hospital.
mineral-homeostasis in continuous renal replacement therapy

Conditions: Acute Renal Failure

Summary: acute renal failure is a common complication in intensive care unit patients. in 10% of cases renal replacement therapy becomes necessary. current devices have increase filter patency and efficacy. however, magnesium, calcium and phosphate are eliminated as well. however, the extend of this elimination hase not been quantified. thus, we want to 1. record retrospectively how often abnormal values for phosphate, magnesium and calcium occurred during routine renal replacement therapy in 2011 and 2012. 2. prospectively evaluate the same parameters during routine treatment in 2013 and 2014


Eligibility criteria:
inclusion criteria: * intensive care unit patients with acute renal failure undergoing continuous renal replacement therapy * older than 18 years of age exclusion criteria: * age less than 18 years * pregnancy * contraindications against continuous renal replacement therapy
beta-glucan effects on lipid profile, glycemia and intestinal health (belt)

Conditions: Atherosclerosis

Summary: this will be a randomized, placebo-controlled, clinical trial carried out on moderately hypercholesterolemic subjects who will consume 3 g per day of beta-glucans, in order to evaluate the effects on lipid profile, glycemia and intestinal function

in order to assess the mid term effects of beta-glucans on lipid profile, glycemia and intestinal function, moderately hypercholesterolemic subjects will be involved in a cross-over study and supplemented for 8 weeks with 3 g/day of beta-glucans or placebo. the two intervention periods will be spaced by a 4 week washout period

Eligibility criteria:
inclusion criteria: * total cholesterol between 200 and 240 mg/dl and/or ldl cholesterol between 130 and 190 mg/dl * triglycerides lower than 200 mg/dl * cardiovascular risk at 10 years lower than 10% * informed consent exclusion criteria: * secondary prevention for cardiovascular diseases * tg \> 400 mg/dl, hdl-c \< 35 mg/dl * bmi higher than 30 * assumption of lipid lowering drug or supplement with fibre or probiotics during the last 2 months * alcohol abuse * food allergy * alterations in thyroid, liver, or kidney functions, muscle diseases * diabetes, irritable bowel syndrome or chronic disturbed gut function
pars plana surgical capsulotomy for posterior capsular opacification

Conditions: Blindness

Summary: cataract is a leading cause of global blindness. after cataract surgery nearly half of the people become blind due to posterior capsular opacification. the only solution for this problem is laser capsulotomy. laser machine is not available in remote areas especially in underdeveloped countries. the solution of this problem is surgical capsulotomy which can be performed any where.

posterior capsular opacification is treated by yag laser capsulotomy. this require sophisticated technology ans specific environment which is not possible in underdeveloped countries. we describe a method in which posterior capsular opacification could be managed by using only a 27 gauge needle through pars plana. opacified posterior capsule is under tension that is why a small puncture results in a large central opening

Eligibility criteria:
inclusion criteria: * patients with posterior capsular opacification * both sexes * all ages exclusion criteria: * retinal disease * uncontrolled glaucoma * corneal opacity

Keywords: pars plana surgical capsulotomy posterior capsule opacification visual outcome complications
comparison of [68ga]gafapi-46 pet/ct and [18f]fdg pet/ct findings in breast carcinoma

Conditions: Breast Neoplasms; Positron Emission Tomography; Fibroblast Activation Protein Inhibitor; Fluorodeoxyglucose F18

Summary: the aim of this study is to compare the diagnostic performance of 68ga-fapi-46 pet/ct and 18f-fdg pet/ct in primary and metastatic lesions of breast cancer and to reveal the best diagnostic imaging time of 68ga-fapi-46 pet/ct.

participants with breast carcinoma will undergo contemporaneous 18f-fdg and 68ga-fapi pet/ct. tumor uptake will be quantified by the maximum standard uptake value (suvmax). the sensitivity, specificity, positive predictive value (ppv), negative predictive value (npv) and accuracy of 18f-fdg and 68ga-fapi pet/ct will be calculated and compared to evaluate the diagnostic efficacy. in addition, best diagnostic imaging time of 68ga-fapi-46 pet/ct will be evaluated at 10th, 30th and 60th minute scan time.

Eligibility criteria:
inclusion criteria: * adult participants (aged 18 years or order); * participants with newly diagnosed breast carcinoma; * pathology confirmed by lesion tru-cut biopsy; * participants who were able to provide informed consent. exclusion criteria: * participants with non-malignant lesions; * participants with pregnancy; * the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
a phase i study of pazopanib in adult patients with liver cancer

Conditions: Carcinoma, Hepatocellular

Summary: liver cancer is a good target for anti-angiogenic treatments such as pazopanib. the effect of pazopanib in patients with liver cancer are unknown. this study is designed to evaluate the safety, tolerability and best dose of pazopanib to be given to patient with liver cancer.


Eligibility criteria:
inclusion criteria: * diagnosis of advanced liver cancer adequate bone marrow, liver and kidney function * any local therapy for tumor must have been completed at least 4 weeks prior to enrolling in study exclusion criteria: * pregnant or breastfeeding * any serious or unstable medical or psychiatric conditions * history of metastases to central nervous system * history of ulcer, inflammatory bowel disease or disease of the gut * history of hiv, or uncontrolled infection * have had a cardiac condition or stoke during the past 6 months * high blood pressure * have had a blood clot during the past 6 months * history of bleeding blood vessels

Keywords: pazopanib liver cancer hepatocellular cancer
concomitant use of hepatitis a vaccine, inactivated with haemophilus b conjugate vaccine (meningococcal protein conjugate) and diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed given to healthy children 15 months of age (v251-068)

Conditions: Hepatitis A Virus

Summary: this two-stage study evaluates the immunogenicity, safety, and tolerability of the administration of vaqta™ (hepatitis a vaccine, inactivated) concomitantly with pedvaxhib™ (haemophilus b conjugate vaccine \[meningococcal protein conjugate\]) and infanrix™ (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, glaxosmithkline) versus the administration of vaqta™ in healthy children 15 months of age at study entry.

in stage i, vaqta™ given concomitantly with infanrix™ and/or pedvaxhib™ was evaluated. in stage 2: two (2) doses of the vaqta™ vaccine were administered at least 6 months apart. safety data was collected after each dose.

Eligibility criteria:
inclusion criteria: * stage 1) healthy males and females 15 months of age with no active liver disease and a negative history of hepatitis a who have been vaccinated against haemophilus influenzae type b (hib), diphtheria, tetanus, and pertussis diseases * stage 2) healthy males and females 12 to 17 months of age with no active liver disease and a negative history of hepatitis a exclusion criteria: * stage 1) males and females previously vaccinated with hepatitis a vaccine, any immune deficiency, a history of allergy to any of the vaccine components, a history of seizure disorder or a neurologic disorder that would contraindicate pertussis vaccine, or a bleeding disorder * stage 2) males and females previously vaccinated with hepatitis a vaccine, any immune deficiency, a history of allergy to any of the vaccine components, or a history of bleeding disorder

Keywords: hepatitis a virus
collaborative approach to reach everyone with familial hypercholesterolemia (care-fh)

Conditions: Familial Hypercholesterolemia

Summary: diagnosis rates of familial hypercholesterolemia (fh) are low in the united states, despite multiple guidelines and recommendations for screening and treatment of high cholesterol, to prevent heart attacks in those affected. using a stepped-wedge design, the investigators plan to utilize tools from implementation science to improve uptake, acceptability, and sustainability of fh diagnostic programs in primary care settings. if successful, this study will provide tools generalizable to other health care systems to improve fh diagnosis rates.

familial hypercholesterolemia (fh) is a common genetic disorder (prevalence 1 in 250) that requires lifelong sustained medical care. evidence-based guidelines for screening and treatment for fh exist. these include universal screening of children ages 9-11, of adolescents ages 18-20, and of adults ages 40 and above; approved diagnostic tools including lipid panels and genetic testing; and recommendations for initiation of lipid lowering medication. fh diagnosis is currently made too late in life, often after a premature heart attack has occurred creating a care gap that results in excess cardiovascular morbidity and mortality. diagnosing fh in the primary care setting would optimize treatment for individuals with fh and close this care gap. utilizing tools from implementation science and human centered design, and by considering uptake, acceptability, and sustainability of programs related to fh care should improve earlier diagnosis. implementation strategies that include insights from patients, clinicians, and healthcare systems are necessary. the long-term goal is to create an effective fh diagnosis program that is practical and sustainable in the real-world setting. the main objective of this project is to determine the uptake of an fh diagnosis program integrated into primary care practices to promote early identification of adult and pediatric patients that is generalizable to other healthcare settings. the research question is, does using a multi-level implementation strategy package, designed to address the specific needs of patients, clinicians, and healthcare systems, improve the diagnosis and activation of care management for individuals with fh. the specific aims are to: 1) to design a clinical trial to assess multi-level implementation strategies for improving fh diagnosis in an integrated health system, 2) compare fh diagnosis rates among primary care clinicians who receive the implementation strategy package versus those who do not, 3) to measure implementation success of an organized fh diagnosis program, and 4) to explore patient-related service and health outcomes related to an fh diagnosis program.

Eligibility criteria:
inclusion criteria: * primary care clinicians (pediatrician, community medicine, internal medicine) in the geisinger healthcare system exclusion criteria: * none
18f-dopa pet to elucidate the antidepressant mechanism of lurasidone in bipolar disorder

Conditions: Bipolar Depression

Summary: the goal of this project is to understand what causes bipolar disorder and how medications treat bipolar depression. particularly, the project focuses on the importance of dopamine signaling in the process. participants will have two different brain scans (mri and pet scan). they will also have treatment for your depression with an fda approved medication, lurasidone (latuda). the study is funded by the columbia university irving institute to improve the treatment of bipolar disorder.


Eligibility criteria:
inclusion criteria: * bipolar i disorder, bipolar ii disorder or other specified bipolar disorder * currently in a major depressive episode and moderately depressed * age 18-50 years old * patients on psychiatric medications will not be benefitting from those medications * females of childbearing potential must be willing to use an acceptable form of birth control throughout the study exclusion criteria: * diagnosis of schizophrenia or other psychotic disorders, recent alcohol or substance use disorder, recent anorexia or bulimia nervosa * previous failed trial of lurasidone, or had intolerable side effects of lurasidone * significant active physical illness * actively suicidal * ect within the past 6 months * recent pregnancy, abortion or miscarriage or plans to conceive during the study; currently lactating * metal in the body that is not mri compatible * current, past or anticipated exposure to radiation * currently taking an anticoagulant medication
effects of exercise training on cognitive function and neurotrophic factors in overweight adults

Conditions: Cognitive Function; Motor Activity; Obesity

Summary: the brainfit study aims to examine acute effects of high intensity interval- vs resistance or combined program has benefits on cognitive function as well as on secretion and regulation of neurotrophic factors or neurotrophins in a cohort of sedentary, overweight adults (aged 18-30 years) from bogota, colombia.


Eligibility criteria:
inclusion criteria: * written informed consent. * interested in improving health and fitness. * central obesity: waist circumference ≥90cm * body mass index ≥ 26 kg/m(2) exclusion criteria: * systemic infections. * weight loss or gain of \>10% of body weight in the past 6 months for any reason. * currently taking medication that suppresses or stimulates appetite. * uncontrolled hypertension: systolic blood pressure 160 mm hg or diastolic blood pressure 95 mm hg on treatment. * gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy). * asthma. * diagnosed diabetes (type 1 or 2), fasting impaired glucose tolerance (blood glucose 118 mg/dl), or use of any anti-diabetic medications. * currently taking antidepressant, steroid, or thyroid medication, unless dosage is stable (no change for 6 months). * any active use of illegal or illicit drugs. * current exerciser (\>30 min organized exercise per week). * indication of unsuitability of current health for exercise protocol (parq).
treatment of in-stent restenosis 2 study

Conditions: Coronary Restenosis

Summary: the aim of this study is to compare the efficacy of sirolimus-eluting balloon catheters (seb) and iopromide-coated paclutaxel-eluting balloon catheters (peb) in the treatment of bare metal (bms) - or drug-eluting stents restenosis (des-isr).

current therapy for in-stent restenosis (isr) is based on the drug-eluting stents (des) or drug-eluting balloon catheters (deb). in clinical practice, paclitaxel is used as an effective antiproliferative agent loaded into deb (paclitaxel-eluting balloon catheters; peb). in contrast to paclitaxel, sirolimus is difficult to deliver on the balloon surface, due to insufficient tissue uptake and shorter tissue retention of limus drugs. it was found that phospholipid-encapsulated sirolimus nanoparticles could be used for coating balloon catheters to provide efficient drug transfer to vessel wall with high tissue concentration. this prospective randomized non-inferiority study compares the efficacy of new sirolimus-eluting balloon catheters (seb) and iopromide-coated paclutaxel-eluting balloon catheters (peb) in the treatment of bare metal (bms) - or drug-eluting stents restenosis (des-isr). the primary end-point is in-segment late lumen loss (lll) at 12 months as measured by quantitative coronary angiography (qca). secondary end-points are the incidence of binary isr (˃50% ds) and the overall incidence of 12-month major adverse cardiac events (mace; cardiovascular death, non-fatal acute myocardial infarction \[aim\], or target vessel revascularization \[tvr\]).

Eligibility criteria:
inclusion criteria: * patients with bms- or des-isr (˃50% diameter stenosis; ds) * ≥18 years of age * willing to sign an informed consent exclusion criteria: * concomitant diseases with an expected survival time of less than 12 months * or that limited the possibility of control coronary aniography (e.g., advanced renal failure). * impossibility of long-term (6 months) dual antiplatelet treatment

Keywords: in-stent restenosis; sirolimus-; paclitaxel-eluting balloon
determining shapes and dimensions of dental arches for the use in lingual technique.

Conditions: Dental Arch Relationship Anomaly

Summary: this study aims to determine the shape and dimension of dental arches from a lingual perspective, and determine shape and size used for lingual orthodontics.

the study sample comprised 70 caucasian brazilian individuals with normal occlusion and at least four of andrew's six keys. maxillary and mandibular dental casts were digitized (3d) and the images were analyzed by delcam power shapet 2010 software. landmarks on the lingual surface of teeth were selected to determine the shape and size of dental arches.

Eligibility criteria:
inclusion criteria:criterion was that individuals should be at least 15 years of age all permanent teeth in occlusion - exclusion criteria:with no odontogenic abnormalities -

Keywords: orthodontics dental arch orthodontic appliance design.
freedom: following rehabilitation, economics and everyday-dialysis outcome measurements study

Conditions: Kidney Failure, Chronic; End Stage Renal Disease, Requiring Dialysis

Summary: purpose the purpose of this study is to compare the economical impact and clinical parameters of short daily hemodialysis using the nxstage® system one hemodialysis device with thrice-weekly conventional in-center dialysis using a matched cohort from the us renal data system (usrds) database.

in the 21st century, nephrologists in the united states face many challenges including a forecast of decline in physician manpower. challenges that are specific to hemodialysis (hd) include reimbursement constraints, a growing shortage of nurses and major technological advances in dialysis equipment. there is a growing interest in alternative dialysis regimen and frequency, but a lack of patient incentive for self-care dialysis either in the center or in the home setting. the proposed phase 4 post-marketing study plans to explore whether daily hd is economically attractive compared with thrice weekly hd, while improving health-related quality of life and other dialysis adequacy measures. this project is unique as it provides a large prospective cohort of patients converted to daily hd, with a longitudinal follow up and an ability to compare to a matched cohort from the united states renal data services. this study will help develop whether daily dialysis is economically attractive through the use of new technologies that reduce treatment costs and decrease hospitalization rates, with the long-term hope of increasing life expectancy. all patients will have the option to participate in the quotidian dialysis registry, coordinated by the lawson health research institute (lhri) in london, ontario.

Eligibility criteria:
inclusion criteria: * diagnosis of esrd and require dialysis * medicare as primary payor (note: does not include medicare hmo as primary payer) * candidate for daily hemodialysis (defined as 6 or more times per week) * ability to understand and willingness to sign an informed consent statement and a health insurance portability and accountability act of 1996 (hipaa) compliant authorization statement exclusion criteria: * current use of the nxstage system one hemodialysis device * previous enrollment in this study * current enrollment in another investigational drug or device trial which might impact the outcome measures planned in this study * likelihood of not surviving the training period

Keywords: esrd daily hemodialysis hemodialysis kidney failure kidney disease